FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

12 letters match. Newest first.

  1. CCIC Huatongwei International Inspection Co., Ltd.

    FDA warns CCIC Huatongwei after inspection found copied data and missing records in medical device safety tests.

    High risk
  2. Mark J. Savant, M.D

    FDA warns clinical investigator Mark J. Savant, M.D., over protocol dosing and eligibility failures and missing informed consent in a drug trial.

    High risk
  3. Mehran Michael Bahrami, M.D.

    FDA warns clinical investigator Dr. Mehran Michael Bahrami over protocol violations and missing records in investigational drug trials.

    High risk
  4. Louisiana State University Health Science Center IRB

    FDA warns Louisiana State University Health Science Center IRB about missed continuing reviews and unreported study terminations for drug research.

    Medium
  5. Mid-Link Testing Company, Ltd

    FDA warns Mid-Link Testing over unreliable Good Laboratory Practice (GLP) safety data for medical device tests.

    High risk
  6. Sanitation & Environmental Technology Institute dba SDWH

    FDA found GLP violations in SDWH's nonclinical testing of medical devices, raising doubts about safety data.

    High risk
  7. Jeffrey W. Taub, M.D./Children's Hospital of Michigan

    FDA warns Detroit investigator over pediatric drug trial protocol deviations and lapsed IRB approval.

    High risk
  8. Antonio E. Blanco, M.D./Vista Health Research, LLC

    FDA cited Dr. Antonio E. Blanco/Vista Health Research for enrolling ineligible trial subjects and missing required safety imaging.

    High risk
  9. Angela M. Stupi, M.D.

    Clinical investigator Angela M. Stupi, M.D. enrolled ineligible subjects and injected study drug at wrong body sites in two trials.

    High risk
  10. Robert J. Hayashi, M.D./Washington University School of Medicine, Department of Pediatrics

    FDA warned Dr. Robert J. Hayashi over protocol deviations in pediatric drug trials that exposed a child to unnecessary study drug and invasive procedures.

    High risk
  11. Toxikon Corporation/Labcorp Bedford LLC

    FDA warned Toxikon/Labcorp Bedford over GLP violations in a biologics nonclinical study, including incorrect kidney-function calculations and failed QA review.

    Medium
  12. Ignacio J. Rodriguez, MD

    FDA warns Dr. Ignacio J. Rodriguez for enrolling ineligible subjects and giving study drug without required checks in a clinical trial.

    High risk